EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Radiotherapy and CDK inhibitors: Opportunities and risks

T Brion, L Quéro

Cancer/Radiothérapie · 2022-10 · 26 (6-7) · 968-972

DOI: 10.1016/j.canrad.2022.06.017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer/Radiothérapie, 2022-10. Verfasst von T Brion und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institut Gustave-Roussy, département d'oncologie radiothérapie, 114, rue Edouard-Vaillant, Villejuif, France. Electronic address: thomas.brion@gustav…. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CDK4/6 inhibitors are nowadays commonly used in metastatic HR+/HER2- breast cancer. Herein, we report a literature review regarding the benefits and risks of their combination with radiotherapy. Numerous pre-clinical studies have indeed shown a potential synergistic effect of these treatments in combination with radiotherapy in various types of cancers. On the other hand, some retrospective clinical studies have reported increased acute toxicity in case of digestive or pulmonary irradiation; therefore, it is advisable to discontinue CDK4/6 inhibitors before starting irradiation. Several prospective clinical trials are currently ongoing to assess the feasibility of this combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4FemaleHumansProspective StudiesProtein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesRetrospective Studies

Stichwörter der Autor:innen

Cyclin-dependent kinase 4Cyclin-dependent kinase 6Kinase-4 cycline-dépendanteKinase-6 cycline-dépendanteRadiosensibilisationRadiosensitizationRadiotherapyRadiothérapieToxicityToxicité

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Institut Gustave-Roussy, département d'oncologie radiothérapie, 114, rue Edouard-Vaillant, Villejuif, France. Electronic address: thomas.brion@gustaveroussy.fr.
  • Inserm U1160, université Paris Cité, 1, avenue Claude-Vellefeaux, 75010 Paris, France; Hôpital Saint-Louis, service de cancérologie-radiothérapie, 1, avenue Claude-Vellefeaux, 75010 Paris, France.

Zitieren

APA

Brion, T., & Quéro, L. (2022). Radiotherapy and CDK inhibitors: Opportunities and risks. Cancer/Radiothérapie, 26(6-7), 968-972. https://doi.org/10.1016/j.canrad.2022.06.017

Vancouver

Brion T, Quéro L. Radiotherapy and CDK inhibitors: Opportunities and risks. Cancer/Radiothérapie. 2022;26(6-7):968-972. doi:10.1016/j.canrad.2022.06.017

BibTeX
@article{Brion2022,
  author = {Brion, T and Quéro, L},
  title = {Radiotherapy and CDK inhibitors: Opportunities and risks},
  journal = {Cancer/Radiothérapie},
  year = {2022},
  volume = {26},
  number = {6-7},
  pages = {968--972},
  doi = {10.1016/j.canrad.2022.06.017}
}
Kostenlos starten →